Skip to content
  • Argentina
  • Brazil
  • Canada
  • Chile
  • Colombia
  • Europe
  • France
  • Germany
  • India
  • Italy
  • Japan
  • Korea
  • Mexico
  • Perú
  • Russia
  • Spain
  • Taiwan
  • The Middle East
  • Turkey
  • United Kingdom
  • United States
  • Vietnam
  • France
    • +34 96 390 53 10 Request Information
    • +34 96 390 53 10 Request Information
    FranceFrance
    • France
      • Part of brands: |
        • Nous Vous Guidons
          • Fertilité
          • Prevent inherited diseases
          • Worry-free pregnancy
        • Santé Reproductive
          • Specialists
            • ALICE
            • EMMA
            • ERA
            • EndomeTRIO
            • EMBRACE
            • CGT
            • NACE
            • PGT-A
            • PGT-M
            • POC
            • SAT
          • Patients
            • ALICE
            • EMMA
            • ERA
            • EndomeTRIO
            • EMBRACE
            • CGT
            • NACE
            • PGT-A
            • PGT-M
            • SAT
            • POC
        • À Propos de Nous
          • Igenomix Recherche
          • À propos d’Igenomix
        • Webinaires
        Genomics Precision Diagnostic > Metabolic Precision Panel > Lysosomal Storage Diseases Precision Panel

        Lysosomal Storage Diseases Precision Panel

        Lysosomal Storage Diseases (LSD) are a group of dozens of inherited disorders that result from the accumulation of undigested or partially processed macromolecules inside organelles called lysosomes.
        Overview
        Indication
        Clinical Utility
        Genes & Diseases
        Methodology
        References

        Overview

        • Lysosomal Storage Diseases (LSD) are a group of dozens of inherited disorders that result from the accumulation of undigested or partially processed macromolecules inside organelles called lysosomes. Lysosomes are responsible for the physiologic turnover and digestion of cell constituents and do so with the help of catabolic enzymes. The accumulation of products inside the lysosomes results in cellular dysfunction and clinical abnormalities. Organomegaly, connective-tissue, ocular pathology and central nervous system dysfunction. It is transmitted in an autosomal recessive pattern.  

        • The Igenomix Lysosomal Storage Diseases Precision Panel can be used to make an accurate and directed diagnosis as well ultimately leading to a better management and prognosis of the disease. It provides a comprehensive analysis of the genes involved in this disease using next-generation sequencing (NGS) to fully understand the spectrum of relevant genes involved.  

        Indication

        • The Igenomix Lysosomal Storage Diseases Precision Panel is indicated for those patients with a clinical suspicion or diagnosis with or without the following manifestations: 
          • Intellectual disability  
          • Delayed physical development 
          • Seizures 
          • Facial and bone deformities 
          • Joint stiffness and pain  
          • Difficulty breathing
          • Vision and hearing difficulties  
          • Anemia, nosebleeds and easy bleeding or bruising
          • Enlarged liver or spleen  

        Clinical Utility

        The clinical utility of this panel is: 

        • The genetic and molecular confirmation for an accurate clinical diagnosis of a symptomatic patient.  
        • Early initiation of treatment with a multidisciplinary team in the form enzyme replacement therapy, substrate reduction therapy, chaperone therapy and nutritional recommendations and frequent consultations to monitor possible complications.  
        • Risk assessment and genetic counselling of asymptomatic family members according to the mode of inheritance. 
        • Improvement of delineation of genotype-phenotype correlation. 

        Genes & Diseases

        See all genes and diseases

        GENE 

        OMIM DISEASES 

        INHERITANCE* 

        % GENE COVERAGE (20X) 

        HGMD** 

        ASAH1 

        Farber Lipogranulomatosis,
         
        Spinal Muscular Atrophy 

        AR 

        99.98 

        69 of 70 

        ATP13A2 

        Kufor-Rakeb Syndrome,
        Spastic Paraplegia,
        Neuronal Ceroid
        Lipofuscinosis
         

        AR 

        99.97 

        53 of 53 

        CA2 

        Osteopetrosis,
        Tubular Acidosis
         

        AR 

        100 

        36 of 36 

        CLCN7 

        Hypopigmentation,
        Osteopetrosis
         

        AD,AR 

        99.85 

        109 of 111 

        CLN3 

        Ceroid
         Lipofuscinosis 

        AR 

        99.93 

        73 of 75 

        CLN5 

        Ceroid 
        Lipofuscinosis 

        AR 

        99.56 

        52 of 55 

        CLN6 

        Ceroid 
        Lipofuscinosis 

        AR 

        99.94 

        98 of 99 

        CLN8 

        Ceroid Lipofuscinosis,
        Progressive Epilepsy-
        Intellectual Disability
        Syndrome
         

        AR 

        100 

        44 of 45 

        CTSD 

        Ceroid
        Lipofuscinosis 

        AR 

        100 

        18 of 18 

        CTSF 

        Ceroid
        Lipofuscinosis 

        AR 

        92.18 

        12 of 12 

        DNAJC5 

        Ceroid 
        Lipofuscinosis 

        AD 

        100 

        2 of 2 

        GALNS 

        Morquio
         
        Syndrome 

        AR 

        100 

        344 of 348 

        GBA 

        Dementia,
        Gaucher Disease,
        Parkinson Disease
         

        AD,AR 

        100 

        469 of 471 

        GLA 

        Fabry Disease 

        X,XR,G 

        98 

        – 

        GLB1 

        Gm1-Gangliosidosis,
        Morquio 
        Syndrome 

        AR 

        100 

        242 of 243 

        GNPTAB 

        Mucolipidosis 

        AR 

        100 

        279 of 280 

        GRN 

        Ceroid Lipofuscinosis,
        Frontotemporal Lobar
         
        Degeneration,
         
        Semantic Dementia 

        AD,AR 

        100 

        220 of 229 

        IDS 

        Mucopolysaccharidosis 

        X,XR,G 

        99.86 

        – 

        IDUA 

        Hurler Syndrome, 
        Scheie Syndrome 

        AR 

        99.73 

        287 of 292 

        KCTD7 

        Epilepsy 

        AR 

        99.99 

        40 of 40 

        LAMP2 

        Danon Disease,
        Glycogen Storage
        Disease
         

        X,XD,G 

        99.96 

        – 

        LIPA 

        Cholesteryl Ester Storage
        Disease, Wolman Disease
         

        AR 

        99.91 

        103 of 104 

        LMBRD1 

        Methylmalonic Aciduria
        , Methylmalonic 
        Acidemia,
        Homocystinuria
         

        AR 

        99.88 

        8 of 8 

        MAN2B1 

        Mannosidosis 

        AR 

        100 

        149 of 149 

        MANBA 

        Mannosidosis 

        AR 

        99.98 

        20 of 20 

        MFSD8 

        Ceroid Lipofuscinosis,
        Macular 
        Dystrophy 

        AR 

        100 

        63 of 63 

        MYO5A 

        Griscelli Syndrome,
        Neuroectodermal 
        Melanolysosomal 
        Disease
         

        AR 

        100 

        10 of 10 

        NPC1 

        Niemann-Pick 
        Disease 

        AR 

        97 

        503 of 505 

        NPC2 

        Niemann-Pick
         
        Disease 

        AR 

        100 

        27 of 27 

        OCRL 

        Dent Disease,
        Lowe 
        Oculocerebrorenal 
        Syndrome
         

        X,XR,G 

        100 

        – 

        PPT1 

        Ceroid 
        Lipofuscinosis 

        AR 

        100 

        81 of 81 

        PSAP 

        Combined Saposin 
        Deficiency, Gaucher
        Disease, 
        Krabbe 
        Disease, Metachromatic
        Leukodystrophy,
        Encephalopathy
         

        AR 

        100 

        33 of 33 

        SCARB2 

        Action Myoclonus-Renal
         Failure Syndrome,
        Gaucher 
        Disease, 
        Unverricht-Lundborg 
        Disease 

        AR 

        99.95 

        29 of 29 

        SMPD1 

        Niemann-Pick 
        Disease 

        AR 

        99.98 

        258 of 258 

        TNFRSF11B 

        Paget Disease Of Bone,
        Calcium Pyrophosphate
        Deposition
         

        AR 

        99.98 

        16 of 16 

        TPP1 

        Ceroid Lipofuscinosis, 
        Spinocerebellar 
        Ataxia
         

        AR 

        100 

        147 of 147 

        TPP2 

        Autoimmune
        Hemolytic 
        Anemia–
        Autoimmune Thrombocytopenia-
        Primary
        Immunodeficiency Syndrome
         

        – 

        99.84 

        11 of 11 

         * Inheritance: AD: Autosomal Dominant; AR: Autosomal Recessive; X: X linked; XLR: X linked Recessive; Mi: Mitochondrial; Mu: Multifactorial 

        ** HGMD: Number of clinically relevant mutations according to HGMD 

        Methodology

        References

        See scientific referrals

        Platt, F. M., d’Azzo, A., Davidson, B. L., Neufeld, E. F., & Tifft, C. J. (2018). Lysosomal storage diseases. Nature Reviews Disease Primers, 4(1), 1-17. https://doi.org/10.1038/s41572-018-0025-4 

        Platt, F., Boland, B., & van der Spoel, A. (2012). Lysosomal storage disorders: The cellular impact of lysosomal dysfunction. Journal Of Cell Biology, 199(5), 723-734. doi: 10.1083/jcb.201208152 

        Marques, A., & Saftig, P. (2019). Lysosomal storage disorders – challenges, concepts and avenues for therapy: beyond rare diseases. Journal of cell science, 132(2), jcs221739. https://doi.org/10.1242/jcs.221739 

        Platt, F. M., d’Azzo, A., Davidson, B. L., Neufeld, E. F., & Tifft, C. J. (2018). Lysosomal storage diseases. Nature reviews. Disease primers, 4(1), 27. https://doi.org/10.1038/s41572-018-0025-4 

        Faverio, P., Stainer, A., De Giacomi, F., Gasperini, S., Motta, S., Canonico, F., Pieruzzi, F., Monzani, A., Pesci, A., & Biondi, A. (2019). Molecular Pathways and Respiratory Involvement in Lysosomal Storage Diseases. International journal of molecular sciences, 20(2), 327. https://doi.org/10.3390/ijms20020327 

        Platt, F. M., Boland, B., & van der Spoel, A. C. (2012). The cell biology of disease: lysosomal storage disorders: the cellular impact of lysosomal dysfunction. The Journal of cell biology, 199(5), 723–734. https://doi.org/10.1083/jcb.201208152 

        Parenti, G., Andria, G., & Ballabio, A. (2015). Lysosomal storage diseases: from pathophysiology to therapy. Annual review of medicine, 66, 471–486. https://doi.org/10.1146/annurev-med-122313-085916 

        BROCHURE

        Download

        Request Information


        • reCAPTCHA demo: Simple page

        Fertilité

        Fertilité
        Éviter les maladies génétiques

        Test prénatal non-invasif

        Pour voir le certificat d'accréditation, l'annexe technique associée et la liste des tests accrédités, cliquez sur ce lien.

        Nos services

        Nos services
        Patients
        D'envoyer les échantillons
        Manuel d'utilisateur

        À propos d’Igenomix

        À propos d’Igenomix
        Igenomix dans le monde
        Quality
        Work with us

        SUIVRE IGENOMIX

          + 96 390 53 10
        Écrivez-nous
        • Argentina
        • Brazil
        • Canada
        • Chile
        • Colombia
        • Europe
        • France
        • Germany
        • India
        • Italy
        • Japan
        • Korea
        • Mexico
        • Perú
        • Russia
        • Spain
        • Taiwan
        • The Middle East
        • Turkey
        • United Kingdom
        • United States
        • Vietnam
        France

        [2021] © Igenomix Politique de confidentialité Politique de qualité Note juridique Politique de cookiesActualités et presse 

        Demander des informations


        • reCAPTCHA demo: Simple page

        • Nous Vous Guidons
          • Fertilité
          • Prevent inherited diseases
          • Worry-free pregnancy
        • Santé Reproductive
          • Specialists
            • ALICE
            • EMMA
            • ERA
            • EndomeTRIO
            • EMBRACE
            • CGT
            • NACE
            • PGT-A
            • PGT-M
            • POC
            • SAT
          • Patients
            • ALICE
            • EMMA
            • ERA
            • EndomeTRIO
            • EMBRACE
            • CGT
            • NACE
            • PGT-A
            • PGT-M
            • SAT
            • POC
        • À Propos de Nous
          • Igenomix Recherche
          • À propos d’Igenomix
        • Webinaires
        • France
        • +34 96 390 53 10 Request Information

        We are using cookies to give you the best experience on our website.

        You can find out more about which cookies we are using or switch them off in settings.

        France
        Powered by  GDPR Cookie Compliance
        Privacy Overview

        This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.

        Strictly Necessary Cookies

        Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.

        If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.